Nucala vs Trelegy Ellipta
Side-by-side cost comparison based on Medicare Part D data
Nucala
Mepolizumab
Manufactured by GlaxoSmithKline
Trelegy Ellipta
Fluticasone/Umeclidinium/Vilanterol
Manufactured by GlaxoSmithKline
Trelegy Ellipta costs 86% less per claim than Nucala ($380.00 vs $2,720.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Nucala | Trelegy Ellipta |
|---|---|---|
| Avg Cost Per Claim | $2,720.00 | $380.00 |
| Total Medicare Spending | $1.5B | $2.9B |
| Total Beneficiaries | 48,000 | 865,000 |
| Total Claims | 564,000 | 7,560,000 |
| Annual Cost/Patient | $31,958.00 | $3,325.00 |
| Year-over-Year Change | +12.4% | +19.8% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Sep 26, 2030 |
| Manufacturer | GlaxoSmithKline | GlaxoSmithKline |
| Condition | Asthma/COPD | Asthma/COPD |
| Generic Name | Mepolizumab | Fluticasone/Umeclidinium/Vilanterol |
Nucala vs Trelegy Ellipta: What the Data Shows
Nucala (Mepolizumab) and Trelegy Ellipta (Fluticasone/Umeclidinium/Vilanterol) are both used to treat asthma/copd. Based on Medicare Part D data, Trelegy Ellipta costs $380.00 per claim, which is 86% less than Nucala at $2,720.00 per claim.
Medicare spent $1.5B on Nucala and $2.9B on Trelegy Ellipta. In terms of patient reach, Trelegy Ellipta serves more beneficiaries (865,000 vs 48,000).
Year-over-year spending changed +12.4% for Nucala and +19.8% for Trelegy Ellipta. Nucala saw significant spending growth, suggesting increased utilization or price increases. Trelegy Ellipta saw significant spending growth, suggesting increased utilization or price increases.
Nucala has a generic available, while Trelegy Ellipta remains brand-only until its patent expires Sep 26, 2030.
Frequently Asked Questions
Trelegy Ellipta is cheaper at $380.00 per claim, compared to $2,720.00 for Nucala. That makes Trelegy Ellipta about 86% less expensive per claim based on Medicare Part D data.
Yes, both Nucala and Trelegy Ellipta are used to treat asthma/copd. Your doctor can help determine which medication is more appropriate for your specific situation.
Nucala has a generic version (Mepolizumab) available, which is typically much cheaper. Trelegy Ellipta is currently brand-only, with patent expiring Sep 26, 2030.
Medicare Part D spent $1.5B on Nucala covering 48,000 beneficiaries, and $2.9B on Trelegy Ellipta covering 865,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.